Friday, 16 October 2026European Markets

EUROCASTLE INVEST. Stock Bullish Momentum With A 20% Rise In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of EUROCASTLE INVEST. (AEX-Index: ECT.AS) rose by a staggering 20.83% in 10 sessions from €6 to €7.25 at 05:09 EST on Tuesday, after four sequential sessions in a row of losses. AEX-Index is sliding 0.48% to €768.98, following the last session's downward trend.

EUROCASTLE INVEST.'s last close was €6.75, 36.92% below its 52-week high of €10.70.

About EUROCASTLE INVEST.

Eurocastle Investment Limited is a publicly traded closed-ended investment company that focuses on investing in performing and nonperforming loans and other real estate related assets primarily in Italy. The Company is Euro denominated and is listed on Euronext Amsterdam under the symbol “ECT”. Eurocastle is managed by an affiliate of Fortress Investment Group LLC, a leading global investment manager. For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.

Earnings Per Share

As for profitability, EUROCASTLE INVEST. has a trailing twelve months EPS of €-0.58.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -3.2%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 65.7%, now sitting on 475k for the twelve trailing months.

Yearly Top and Bottom Value

EUROCASTLE INVEST.'s stock is valued at €7.25 at 05:09 EST, way below its 52-week high of €10.70 and above its 52-week low of €6.60.

Sales Growth

EUROCASTLE INVEST.'s sales growth is negative 113.8% for the present quarter and negative 113.8% for the next.

Volume

Today's last reported volume for EUROCASTLE INVEST. is 839 which is 1346.55% above its average volume of 58.

More news about EUROCASTLE INVEST. (ECT.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com